DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers
- Conditions
- Interventions
- First Posted Date
- 2023-05-31
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 120
- Registration Number
- NCT05882058
- Locations
- 🇨🇳
960 Hospital of the Chinese People's Liberation Army, Jinan, China
🇨🇳The Second Affiliated Hospital to Nanchang University, Nanchang, China
🇨🇳Shanghai Chest Hospital, Shanghai, China
A Study in Healthy Men to Test How BI 1810631 is Taken up and Processed by the Body
- Conditions
- Interventions
- First Posted Date
- 2023-05-30
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 15
- Registration Number
- NCT05879991
- Locations
- 🇳🇱
ICON, Groningen, Netherlands
A Study to Test How Well Different Doses of Obrixtamig (BI 764532) in Combination With Ezabenlimab Are Tolerated by People With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3
- Conditions
- Interventions
- First Posted Date
- 2023-05-30
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 43
- Registration Number
- NCT05879978
- Locations
- 🇯🇵
National Cancer Center Hospital, Tokyo, Chuo-ku, Japan
🇫🇷HOP Louis Pradel, Bron, France
🇧🇪UNIV UZ Gent, Gent, Belgium
Study of Progression to Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Incidence/Management and Treatment
- Conditions
- First Posted Date
- 2023-05-25
- Last Posted Date
- 2023-05-25
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 200000
- Registration Number
- NCT05875532
- Locations
- 🇺🇸
Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, United States
Burden of Nintedanib Non-adherence Among Idiopathic Pulmonary Fibrosis (IPF) Patients
- First Posted Date
- 2023-05-23
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1798
- Registration Number
- NCT05870956
- Locations
- 🇺🇸
Medicus Economics, LCC, Milton, Massachusetts, United States
A Study to Test How Well BI 1291583 is Tolerated by People With Cystic Fibrosis Bronchiectasis (Clairafly™)
- First Posted Date
- 2023-05-19
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 22
- Registration Number
- NCT05865886
- Locations
- 🇪🇸
Hospital Vall d'Hebron-Barcelona-47683, Barcelona, Spain
🇺🇸University of Kansas Medical Center, Kansas City, Kansas, United States
🇺🇸Northwell Health Physician Partners, New York, New York, United States
A Study in Healthy Men to Test How BI 764198 is Processed in the Body
- Conditions
- Interventions
- First Posted Date
- 2023-05-17
- Last Posted Date
- 2023-11-15
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 24
- Registration Number
- NCT05863130
- Locations
- 🇳🇱
ICON, Groningen, Netherlands
A Study to Test How Well Different Doses of BI 1815368 Are Tolerated by Healthy Men
- First Posted Date
- 2023-05-15
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 59
- Registration Number
- NCT05857878
- Locations
- 🇧🇪
SGS Life Science Services - Clinical Research, Edegem, Belgium
A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Netherton Syndrome
- First Posted Date
- 2023-05-12
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 43
- Registration Number
- NCT05856526
- Locations
- 🇺🇸
Mission Dermatology Center, Rancho Santa Margarita, California, United States
🇺🇸Yale University School of Medicine, New Haven, Connecticut, United States
🇺🇸Virginia Clinical Research, Inc., Norfolk, Virginia, United States
Developing a Screening Tool for Interstitial Lung Disease in People With Rheumatoid Arthritis Using Risk Factors
- Conditions
- First Posted Date
- 2023-05-11
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1350
- Registration Number
- NCT05855109
- Locations
- 🇺🇸
Stanford University School of Medicine, Palo Alto, California, United States
🇺🇸University of Colorado, Aurora, Colorado, United States
🇺🇸Harvard Medical School - Brigham and Women's Hospital, Boston, Massachusetts, United States